5 questions answered from cited research · Plain language
Some evidence links GLP-1 receptor agonists to a modest increase in early-stage diabetic retinopathy, but findings are mixed and may depend on the specific drug and how quickly blood sugar drops.
Read the full answer →Yes, GLP-1 receptor agonists (liraglutide, semaglutide) improve walking distance in people with type 2 diabetes and peripheral artery disease, based on a 2025 meta-analysis of randomized trials.
Read the full answer →Recent studies link PCOS and type 2 diabetes through shared genetic variants, notably the insulin gene VNTR and epigenetic changes in metabolism-related genes.
Read the full answer →Standard treatment for type 2 diabetes includes lifestyle changes (diet, exercise), metformin, other medications like GLP-1 agonists (e.g., semaglutide, tirzepatide), and sometimes insulin, along with monitoring blood sugar and managing cardiovascular risk.
Read the full answer →A Mediterranean diet, regular physical activity, weight loss, and digital health tools can effectively manage type 2 diabetes, with medication support as needed.
Read the full answer →